Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AktiengesellschaftfiledCriticalBayer Schering Pharma Aktiengesellschaft
Priority to CU20060219ApriorityCriticalpatent/CU20060219A7/en
Publication of CU20060219A7publicationCriticalpatent/CU20060219A7/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
La presente invención se refier a nuevas formas de presentación galénicas de liberación controlada de principio activo, que contienen el inhibidor de PDE-5 vardenafilo y/o sales,hidratos, solvatos y/o formas polimóficas del mismo farmacéuticamente eceptables como principio activo, así como a su preparación, La invención se refiere además al uso de estas nuevas formas de presentación galénicas como medicamentos y a su uso para la preparación de medicamentos para el tratamiento y/o prevención de enfermedades en humanos y animales.The present invention relates to new forms of galenic presentation of controlled release of active ingredient, which contain the PDE-5 inhibitor vardenafil and / or pharmaceutically acceptable salts, hydrates, solvates and / or polymorphic forms thereof as active ingredient, as well as to its preparation, The invention also relates to the use of these new forms of galenic presentation as medicaments and their use for the preparation of medicaments for the treatment and / or prevention of diseases in humans and animals.
CU20060219A2006-11-132006-11-13
FORMULATIONS WITH CONTROLLED RELEASE OF ACTIVE PRINCIPLE CONTAINING VARDENAFILO
CU20060219A7
(en)
COMPOUNDS DERIVED FROM PIRROLOPIRIMIDINA, INHIBITORS OF CIANASA JAK3; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF REPLACEMENT OF TRANSPLANTS, AUTOIMMUN DISEASES
PHARMACEUTICAL COMPOSITION THAT INCLUDES DERIVATIVES OF GLUCOPIRANOSIL DIFENYLMETHANE, PHARMACEUTICAL FORM OF THE SAME, PROCEDURE FOR THEIR PREPARATION AND USES OF THE SAME FOR IMPROVED GLUCEMIC CONTROL IN A PATIENT.
Compounds derived from pyrrolo pyridine carboxamides, jak2 inhibitors; pharmaceutical composition comprising them; use in the treatment of myeloproliferative diseases or cancer, such as polycythemia vera, essential thrombocytopenia, multiple myeloma, among others.
Compounds derived from imidazopyrimidine, substituted, pde10a inhibitors; preparation procedure; pharmaceutical composition; and its use for the treatment or prevention of psychotic disorders, schizophrenia, parkinson's disease, multiple sclerosis, among others.
DERIVATIVES OF N- (2-TIAZOLIL) -AMIDA AS INHIBITORS OF GSK-3, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THERAPEUTIC USES.